JP2014521658A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014521658A5 JP2014521658A5 JP2014523092A JP2014523092A JP2014521658A5 JP 2014521658 A5 JP2014521658 A5 JP 2014521658A5 JP 2014523092 A JP2014523092 A JP 2014523092A JP 2014523092 A JP2014523092 A JP 2014523092A JP 2014521658 A5 JP2014521658 A5 JP 2014521658A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- amount
- laquinimod
- day
- glatiramer acetate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161512808P | 2011-07-28 | 2011-07-28 | |
| US61/512,808 | 2011-07-28 | ||
| PCT/US2012/048684 WO2013016684A1 (en) | 2011-07-28 | 2012-07-27 | Treatment of multiple sclerosis with combination of laquinimod and glatiramer acetate |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016230818A Division JP2017081930A (ja) | 2011-07-28 | 2016-11-29 | ラキニモドおよび酢酸グラチラマーを組み合わせた多発性硬化症の治療 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014521658A JP2014521658A (ja) | 2014-08-28 |
| JP2014521658A5 true JP2014521658A5 (https=) | 2015-09-17 |
Family
ID=47597714
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014523092A Withdrawn JP2014521658A (ja) | 2011-07-28 | 2012-07-27 | ラキニモドおよび酢酸グラチラマーを組み合わせた多発性硬化症の治療 |
| JP2016230818A Withdrawn JP2017081930A (ja) | 2011-07-28 | 2016-11-29 | ラキニモドおよび酢酸グラチラマーを組み合わせた多発性硬化症の治療 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016230818A Withdrawn JP2017081930A (ja) | 2011-07-28 | 2016-11-29 | ラキニモドおよび酢酸グラチラマーを組み合わせた多発性硬化症の治療 |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US20130029916A1 (https=) |
| EP (1) | EP2736335A4 (https=) |
| JP (2) | JP2014521658A (https=) |
| KR (1) | KR20140054166A (https=) |
| CN (2) | CN103781354A (https=) |
| AU (2) | AU2012286699A1 (https=) |
| BR (1) | BR112014002095A2 (https=) |
| CA (1) | CA2843433A1 (https=) |
| CL (2) | CL2014000209A1 (https=) |
| EA (1) | EA201490377A1 (https=) |
| HK (2) | HK1198279A1 (https=) |
| IL (1) | IL251397A0 (https=) |
| IN (1) | IN2014MN00333A (https=) |
| MX (1) | MX2014001050A (https=) |
| PE (1) | PE20142319A1 (https=) |
| SG (1) | SG10201606191PA (https=) |
| UY (1) | UY34358A (https=) |
| WO (1) | WO2013016684A1 (https=) |
| ZA (1) | ZA201401371B (https=) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2234485B1 (en) | 2007-12-20 | 2013-11-13 | Teva Pharmaceutical Industries, Ltd. | Stable laquinimod preparations |
| DK2542079T3 (da) | 2010-03-03 | 2014-08-25 | Teva Pharma | Behandling af reumatoid artritis med en kombination af laquinimod og methotrexat |
| SG183512A1 (en) * | 2010-03-03 | 2012-09-27 | Teva Pharma | Treatment of lupus nephritis using laquinimod |
| CA2851525A1 (en) | 2011-10-12 | 2013-04-18 | Teva Pharmaceutical Industries Ltd. | Treatment of multiple sclerosis with combination of laquinimod and fingolimod |
| CN104093310A (zh) | 2012-02-03 | 2014-10-08 | 泰华制药工业有限公司 | 拉喹莫德用于治疗一线抗TNFα疗法失败的克罗恩氏病患者的用途 |
| JP6215238B2 (ja) | 2012-02-16 | 2017-10-18 | テバ ファーマシューティカル インダストリーズ リミティド | Ｎ−エチル−ｎ−フェニル−１，２−ジヒドロ−４，５−ジ−ヒドロキシ−１−メチル−２−オキソ−３−キノリンカルボキサミド、その製剤、および使用 |
| TW201350467A (zh) | 2012-05-08 | 2013-12-16 | Teva Pharma | Ｎ－乙基－４－羥基－１－甲基－５－（甲基（２，３，４，５，６－五羥基己基）胺基）－２－側氧－ｎ－苯基－１，２－二氫喹啉－３－甲醯胺 |
| TW201400117A (zh) | 2012-06-05 | 2014-01-01 | Teva Pharma | 使用拉喹莫德治療眼發炎疾病 |
| TW201410244A (zh) | 2012-08-13 | 2014-03-16 | Teva Pharma | 用於治療ｇａｂａ媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ） |
| EP2916915A4 (en) | 2012-11-07 | 2016-06-22 | Teva Pharma | LAQUINIMOD AMINE SALTS |
| US20160046582A1 (en) | 2013-03-14 | 2016-02-18 | Teva Pharmaceutical Industries Ltd. | Crystals of laquinimod sodium and improved process for the manufacture thereof |
| EP3043647A4 (en) * | 2013-09-12 | 2017-05-10 | Teva Pharmaceutical Industries Ltd. | Gene expression biomarkers of laquinimod responsiveness |
| US20150094332A1 (en) * | 2013-09-27 | 2015-04-02 | Teva Pharmaceutical Industries, Ltd. | Laquinimod Combination Therapy For Treatment Of Multiple Sclerosis |
| EP3068395A4 (en) * | 2013-11-15 | 2017-07-12 | Teva Pharmaceutical Industries Ltd. | Treatment of glaucoma using laquinimod |
| HK1225969A1 (zh) * | 2014-01-17 | 2017-09-22 | Teva Pharmaceutical Industries Ltd | 利用低剂量的拉喹莫德治疗克隆氏病 |
| WO2015168103A1 (en) | 2014-04-29 | 2015-11-05 | Teva Pharmaceutical Industries Ltd. | Laquinimod for the treatment of relapsing-remitting multiple sclerosis (rrms) patients with a high disability status |
| US20150361757A1 (en) * | 2014-06-17 | 2015-12-17 | Baker Hughes Incoporated | Borehole shut-in system with pressure interrogation for non-penetrated borehole barriers |
| EP3193870A4 (en) * | 2014-09-16 | 2018-04-25 | Teva Pharmaceutical Industries Ltd. | Treatment of neurodegenerative diseases with combination of laquinimod and fingolimod |
| US20170028013A1 (en) * | 2015-07-30 | 2017-02-02 | Teva Pharmaceutical Industries, Ltd. | Combination formulation of laquinimod and glatiramer acetate with amino acids |
| KR20200143716A (ko) * | 2018-04-13 | 2020-12-24 | 모데차이 체비온 | 탈수초 치료용 조성물 및 방법 |
| KR20220118419A (ko) | 2019-12-19 | 2022-08-25 | 액티브 바이오테크 에이비 | 과도한 혈관신생과 관련된 안구 질병의 치료를 위한 화합물 |
| KR102350943B1 (ko) * | 2021-07-12 | 2022-01-14 | 주식회사 바움디자인시스템즈 | 집적 회로에 대한 소비 전력을 예측하는 방법 및 이를 수행하는 소비 전력 예측 시스템 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002076503A1 (en) * | 2000-06-20 | 2002-10-03 | Mayo Foundation For Medical Education And Research | Treatment of central nervous system diseases by antibodies against glatiramer acetate |
| EP1778286A4 (en) * | 2004-03-03 | 2009-04-08 | Teva Pharma | COMBINATION THERAPY WITH ACETATE OF GLATIRAMER AND RILUZOLE |
| KR20150065951A (ko) * | 2006-06-12 | 2015-06-15 | 테바 파마슈티컬 인더스트리즈 리미티드 | 안정한 라퀴니모드 제제 |
| ES2329327B1 (es) * | 2008-03-19 | 2010-09-17 | Proyecto De Biomedicina Cima, S.L. | Combinaciones sinergicas de 5'-metiltioadenosina. |
| KR20110048571A (ko) * | 2008-09-03 | 2011-05-11 | 테바 파마슈티컬 인더스트리즈 리미티드 | 면역 기능을 지닌 ２―옥소―１,２―다이하이드로―퀴놀린 조절제 |
| AR073295A1 (es) * | 2008-09-16 | 2010-10-28 | Genentech Inc | Metodos para tratar la esclerosis multiple progresiva. articulo de fabricacion. |
| WO2010070449A2 (en) * | 2008-12-17 | 2010-06-24 | Actavis Group Ptc Ehf | Highly pure laquinimod or a pharmaceutically acceptable salt thereof |
| JP2012530701A (ja) * | 2009-06-19 | 2012-12-06 | テバ ファーマシューティカル インダストリーズ リミティド | 多発性硬化症のラキニモドでの治療 |
| WO2011019375A1 (en) * | 2009-08-10 | 2011-02-17 | Teva Pharmaceutical Industries Ltd. | Treatment of bdnf-related disorders using laquinimod |
| EP2493477B1 (en) * | 2009-10-27 | 2013-10-16 | Wyeth LLC | Bazedoxifene formulations with antioxidants |
| EP2523668A1 (en) * | 2010-01-13 | 2012-11-21 | Ramot at Tel-Aviv University Ltd | Treatment of multiple sclerosis |
-
2012
- 2012-07-27 IN IN333MUN2014 patent/IN2014MN00333A/en unknown
- 2012-07-27 AU AU2012286699A patent/AU2012286699A1/en not_active Abandoned
- 2012-07-27 KR KR1020147005638A patent/KR20140054166A/ko not_active Withdrawn
- 2012-07-27 SG SG10201606191PA patent/SG10201606191PA/en unknown
- 2012-07-27 CN CN201280043755.9A patent/CN103781354A/zh active Pending
- 2012-07-27 HK HK14111812.7A patent/HK1198279A1/xx unknown
- 2012-07-27 MX MX2014001050A patent/MX2014001050A/es unknown
- 2012-07-27 BR BR112014002095A patent/BR112014002095A2/pt not_active IP Right Cessation
- 2012-07-27 CN CN201610302142.2A patent/CN105944081A/zh active Pending
- 2012-07-27 CA CA2843433A patent/CA2843433A1/en not_active Abandoned
- 2012-07-27 JP JP2014523092A patent/JP2014521658A/ja not_active Withdrawn
- 2012-07-27 PE PE2014000132A patent/PE20142319A1/es not_active Application Discontinuation
- 2012-07-27 US US13/560,851 patent/US20130029916A1/en not_active Abandoned
- 2012-07-27 EA EA201490377A patent/EA201490377A1/ru unknown
- 2012-07-27 EP EP12817089.1A patent/EP2736335A4/en not_active Withdrawn
- 2012-07-27 WO PCT/US2012/048684 patent/WO2013016684A1/en not_active Ceased
- 2012-10-01 UY UY0001034358A patent/UY34358A/es not_active Application Discontinuation
-
2014
- 2014-01-28 CL CL2014000209A patent/CL2014000209A1/es unknown
- 2014-02-21 ZA ZA2014/01371A patent/ZA201401371B/en unknown
-
2015
- 2015-07-16 US US14/801,595 patent/US20160038532A1/en not_active Abandoned
-
2016
- 2016-05-06 US US15/148,074 patent/US20160361352A1/en not_active Abandoned
- 2016-07-11 AU AU2016204777A patent/AU2016204777A1/en not_active Abandoned
- 2016-08-24 CL CL2016002132A patent/CL2016002132A1/es unknown
- 2016-11-29 JP JP2016230818A patent/JP2017081930A/ja not_active Withdrawn
- 2016-12-22 HK HK16114575.6A patent/HK1226940A1/zh unknown
-
2017
- 2017-03-27 IL IL251397A patent/IL251397A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014521658A5 (https=) | ||
| US11648232B2 (en) | Methods and compositions for treating excessive sleepiness | |
| JP2014530821A5 (https=) | ||
| JP2010518122A5 (https=) | ||
| JP2013544887A5 (https=) | ||
| HRP20140783T1 (hr) | Uporaba epotilona d u lijeäśenju tau-povezanih bolesti ukljuäśujuä†i alzheimerovu bolest | |
| JP2005510535A5 (https=) | ||
| NZ611628A (en) | Use of laquinimod for reducing fatigue, improving functional status, and improving quality of life in multiple sclerosis patients | |
| CN103732062A (zh) | 治疗多发性硬化以及保持和/或增加髓磷脂含量的方法 | |
| JP2015512406A5 (https=) | ||
| JP2015524444A5 (https=) | ||
| HK1206246A1 (en) | Use of high dose laquinimod for treating multiple sclerosis | |
| JP2013541583A5 (https=) | ||
| JP2010513250A5 (https=) | ||
| TW202333733A (zh) | 一種(6S)-N-[4-({(2S,5R)-5-[(R)-羥基(苯基)甲基]吡咯啶-2-基}甲基)苯基]-4-側氧-4,6,7,8-四氫吡咯并[1,2-a]嘧啶-6-甲醯胺用於夜間頻尿治療劑之醫藥製造之用途 | |
| JP2015522077A5 (https=) | ||
| RU2008119454A (ru) | Лекарственное средство для защиты моторного нейрона у пациентов с боковым амиотрофическим склерозом | |
| CA2859004A1 (en) | Methods and compositions for administration of oxybutynin | |
| CN100518775C (zh) | 一种治疗咳喘的药物组合物及其制剂 | |
| ES2326078T3 (es) | Medicamento destinado al sindrome de la disfuncion de integracion. | |
| CN101677998B (zh) | 包含西洛他唑的治疗精神分裂症药物 | |
| JP2015524460A5 (https=) | ||
| CN109464441B (zh) | 3-乙酰氨基香豆素在制备治疗或预防高尿酸血症及肾损伤的药物中的应用 | |
| JP2016533323A5 (https=) | ||
| WO2016041438A1 (zh) | 一种柚皮苷与盐酸非索非那丁药物组合物及其制剂 |